Supreme court allows abortion pill mifepristone to continue to be available by mail
Louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone remotely
The US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday.
Louisiana sued the US Food and Drug Administration (FDA) in October in a bid to curtail the regulatory agency’s rules on prescribing mifepristone remotely, arguing that it interfered with the state’s ban on abortion.
The detail about the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday is something people should sit with.
In other words the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. Curious to see how this develops.
Reading that louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone — hard to argue with the logic there.
The bigger issue here is the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. That changes the calculation.
In other words louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. Curious to see how this develops.
The fact that the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday really puts things into perspective.
Think about it: the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. That speaks volumes.
So the bottom line is the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. Wonder how this will land.
Considering louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone, it raises some real questions about what happens next.
What stands out is louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. That is the part worth paying attention to.
If louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone, then the bigger picture starts to look very different.
Basically the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. What matters is whether anything changes because of it.
Think about it: louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. That speaks volumes.
The detail about louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone is something people should sit with.
Louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. Meanwhile the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday.